Table 1 Clinicopathological characteristics of the ERpHER2n WGS cohort and total HRD frequency
From: Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
Total cohort | ChemoEndoa | Endo | |
|---|---|---|---|
Number of patients | 502 (100%) | 339 (67.5%) | 138 (27.5%) |
Female/male (%) | 98.8/1.2% | 99.7/0.3% | 97.1/2.9% |
Median age (years) | 65 | 60 | 75 |
Median tumor size and range (mm) | 20 (2–115) | 20 (2–115) | 18 (8–67) |
Nottingham Grade (NHG) | |||
NHG 1 | 8.1% | 6.4% | 10.1% |
NHG 2 | 40.0% | 35.8% | 49.3% |
NHG 3 | 51.8% | 57.9% | 40.6% |
Nodal status | |||
Node-negative (N0) | 47.3% | 38.4% | 62.3% |
Node-positive (N+) | 52.7% | 61.6% | 37.7% |
HER2-low statusb | 84.8% | 84.6% | 85.7% |
PR-status (positive/negative) | 84.8/15.2% | 86.1/13.9% | 81.9/18.1% |
Adjuvant therapy | |||
ChemoEndoa | 71.1% | 100% | 0% |
Endo | 28.9% | 0% | 100% |
Complete overall survival data | 100% | 100% | 100% |
Complete DRFI survival datac | 99.6% | 98.5% | 98.6% |
Germline screening data available | 11.4% | 13.9% | 3.6% |
HRD frequency | 8.4% | 9.1% | 7.2% |
PAM50 subtypes | |||
Basal | 3.3% | 2.1% | 4.3% |
HER2-enriched (HER2E) | 6.3% | 4.0% | 11.6% |
Luminal A (LumA) | 30.9% | 37.1% | 18.1% |
Luminal B (LumB) | 57.7% | 54.1% | 65.9% |
Normal | 1.8% | 2.7% | 0% |
